Introduction
Malignant hyperthermia (MH) is a rare life-threatening response that occurs in genetically susceptible individuals that triggered by exposure to halogenated/volatile anesthetics commonly used during surgery interventions, characterized by muscle rigidity, hyperthermia, rhabdomyolysis, acidosis, tachycardia, and, if untreated, death(1). Dantrolene is a well-known inhibitor of Ca2+ release in skeletal muscle that has been used clinically as first-line therapy for MH(2). A 14-year-old Chinese boy occurred fulminant MH after cervical spine surgery even not exposed to volatile anesthetics or succinylcholine and was successfully cured by combined treatment of intravenous dantrolene, continuous veno-venous hemofiltration (CVVH), and plasma exchange (PE) therapy. In this case, the pharmacokinetics of intravenous dantrolene with CVVH/PE during fulminant malignant hyperthermia were explored. We present the following case in accordance with the CARE reporting checklist.